Skip to content
Home page - Centenary Institute Centenary Institute

Primary menu

  • Research
        • Research

          The latest medical research into our most complex health challenges across biomedical AI, cancer, cardiovascular diseases, inflammation, immunity, age-related, rare and infectious diseases.

          Learn more

        • Biomedical AI
        • Cancer Innovations
        • Cardiovascular Research
        • Healthy Ageing
        • Infection & Immunity
        • Inflammation
        • Rare Diseases & Gene Therapy
        • Laboratories
        • Diseases
        • Expertises
        • Breakthroughs
        • Technologies
          • Clinical Translation
  • Support us
        • Support us

          By supporting the Centenary Institute you can help improve human health through excellence in medical research

          Learn more

        • Workplace giving
        • Host or join a fundraiser
        • Gift in your Will
        • Donate in Memory
        • Community and research
  • Careers & students
        • Careers & Students

          Postdoctoral and postgraduate students can work alongside world-leading medical researchers within state-of-the-art research facilities.

        • Career Opportunities
        • Student Opportunities
  • Health hub
        • Health hub

          A range of practical information to assist in the possible preventions to disease through evidence-based research on how the body works.

          Learn more

        • Inflammation
        • The Good Gut Anti-Inflammatory Diet
          • Healthy Recipes
        • Ageing
        • Exercise Snack Program
  • News & events
        • News & Events

          Explore the latest research breakthroughs and ways you can take part in our series of digital and in-person events

        • News
        • Events
        • Media Hub
          • Statements
        • Real stories
  • About us
        • About us

          We are world-leading independent medical research institute that drives collaboration to accelerate and translate solutions to our most complex health challenges

          Learn more

        • Governance
        • Corporate information
        • Annual reports
        • Our researchers
          • Animals in research
        • Contact
  • Donate
    Centenary Institute > News > New discovery to aid treatment of problem infant hemangiomas

New discovery to aid treatment of problem infant hemangiomas

Date time 23 December, 2021
News Type News type Media release
A/Prof Mathias Francois
Research led by the Centenary Institute and the Harvard Medical School, Boston, shows that a compound present in current beta blocker treatments could be repurposed to increase efficiency and safety of infantile hemangioma therapies.

Infantile hemangioma, a type of birthmark that occurs when a cluster of blood vessels grows in or under a baby’s skin, usually resolves on its own after a few years. However, infantile hemangiomas can cause complications such as airway or visual obstruction, cardiac failure, feeding difficulties, ulceration and disfigurement.

Propranolol and atenolol, both beta blockers, are commonly used as the mainstay treatment for infantile hemangiomas, shrinking the aberrant blood vessels but the treatment is not effective for around 20% of patients. Further, the molecular mode of action of the treatment is not fully understood by researchers.

For over 60 years propranolol has been given to humans as a beta blocker, mostly to manage blood pressure issues. Amazingly, this drug exists as a 50/50 mixture of two forms of the same molecule: the R and S enantiomers. Solely, the S-enantiomer is known to act as a beta blocker while the R-enantiomer has been considered as a by-product of chemistry synthesis with low to no biological activity.

In a new study, published in The Journal of Clinical Investigation, scientists discovered that R(+) enantiomers were able to inhibit infantile hemangioma blood vessels in pre-clinical models via targeting a molecular switch that is essential to gene expression of the vasculature during development. In particular, R-enantiomer blocks the activity of a protein named SOX18 which is essential to the transition from hemangioma stem cell to hemangioma endothelial cells.

The Centenary Institute’s Associate Professor Mathias Francois, senior author of the study and Head of the David Richmond Laboratory for Cardiovascular Development said that they had used a combination of pre-clinical mouse models of hemangioma based on patient derived hemangioma stem cells, together with advanced molecular imaging techniques to make their discovery. In particular the use of single molecule imaging in real time enabled the research team to firmly establish that R-enantiomer of propranolol directly engaged with the SOX18 protein.

“Approximately twenty percent of infantile hemangioma patients do not respond to current beta blocker treatments. Also, many patients suffer from beta blocker side effects including sleep disorders, bronchospasm, bradycardia, hypotension and hypoglycaemia,” Associate Professor Francois said.

“We believe that R(+) enantiomers, the ‘active ingredient’ in beta blockers inhibiting sick blood vessels, could  be further developed to increase the efficiency of infantile hemangioma treatments. Such an approach would also negate side effects resulting from current beta blocker use.”

Associate Professor Francois says the finding has the potential to reposition the clinical management of this disease and will provide non-responder patients with a new therapeutic option.

The research team hope to be able to validate their findings in the clinic with hemangioma patients as a next step.

Themes

  • Cardiovascular Research

    Cardiovascular Research

Media enquires

For all media and interview enquiries, please contact Alison Mendel

Phone number Phone Number +61 434 629 469

Email Email a.mendel@centenary.org.au

Media Release

New discovery to aid treatment of problem infant hemangiomas

Download

Recent Stories

  • New platform to evolve proteins for better therapies

    Researchers from the Centenary Institute, in collaboration with the University of Sydney, have developed a powerful new tool to evolve proteins directly within mammalian cells, offering a more effective way to design medical treatments tailored to the human body.
    News Type: Media release
    Date 08 May 2025
  • Turning off protein may help prevent liver cancer

    New research from the Centenary Institute has found that switching off a specific protein in liver cells may help prevent the early development of liver cancer.
    News Type: Media release
    Date 16 Apr 2025
  • Event shines spotlight on genetic heart disease in young people

    The Centenary Institute has hosted a community event, titled ‘A Needle in a Haystack: Unlocking the Secrets of Genetic Heart Conditions’. The event aimed to advance understanding of inherited heart disease and sudden cardiac death in young people.
    News Type: Community
    Date 10 Apr 2025
  • Finding answers for sudden cardiac death in young people

    Each week in Australia, up to three young people die suddenly and unexpectedly from sudden cardiac death, often due to an undiagnosed genetic heart condition. These conditions typically go unnoticed until tragedy strikes, leaving families devastated and searching for answers.
    News Type: Media release
    Date 02 Apr 2025

Subscribe to receive news on
research updates and free events

Newsletter

The Centenary Institute is a world-leading independent Medical Research Institute.

We acknowledge the Gadigal of the Eora Nation, the traditional custodians of the Country on which the Centenary Institute stands.

About

  • About
  • Governance
  • Corporate information

Research

  • Our researchers
  • News
  • Media hub

Careers & studies

  • Career opportunities
  • Life at Centenary

Links

  • Contact
  • Privacy statement

Contact us

Building 93, Royal Prince Alfred Hospital
Missenden Rd
Camperdown NSW 2050 Australia
Telephone +61 2 9565 6100
Fax +61 2 9565 6101

Contact Privacy

Centenary Institute ABN 22 654 201 090 (DGR 1) • Centenary Institute Medical Research Foundation ABN 85 778 244 012 (DGR 2)
© 2017 Centenary Institute of Cancer Medicine and Cell Biology.

  • Linkedin
  • Facebook
  • Twitter
  • Youtube
  • Instagram